Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIFECTA: Nadofaragene Firadenovec With Neoadjuvant Chemotherapy and Durvalumab in Muscle Invasive Bladder Cancer
NCT07332351Phase 2Not yet recruiting
- Sponsor
- University of Washington
- Start
- Dec 2026
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of nadofaragene firadenovec in muscle-invasive bladder cancer (MIBC), sponsored by University of Washington. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
nadofaragene firadenovec
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07332351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07332351.